What is Roehrero and how is it used by the Shipibo people?

Roehrero is the Shipibo-Conibo name for Brugmansia suaveolens, a tropane alkaloid-rich plant used in Amazonian shamanic practice as a visionary plant teacher for ceremonial diagnosis and healing. Trained curanderos administer carefully prepared decoctions in ritualized contexts to induce altered states mediated by scopolamine's antagonism of muscarinic acetylcholine receptors in the brain. Due to the plant's extreme toxicity, its ceremonial use is strictly supervised and it is never considered appropriate for unsupervised self-administration.

What are the main psychoactive compounds in Brugmansia suaveolens?

The primary psychoactive compounds are the tropane alkaloids scopolamine (hyoscine), atropine, and hyoscyamine, all of which competitively antagonize muscarinic acetylcholine receptors throughout the central and peripheral nervous systems. Scopolamine has the highest CNS penetration and is responsible for the plant's characteristic deliriant, amnestic, and hypnagogic hallucinogenic effects. These same compounds are the source of the plant's significant toxicity, with a very narrow margin between psychoactive and lethal doses.

Is Brugmansia suaveolens safe to use or consume?

Brugmansia suaveolens is not safe for unsupervised consumption in any form; all plant parts including flowers, leaves, seeds, and bark contain toxic concentrations of anticholinergic tropane alkaloids capable of causing severe anticholinergic toxidrome, including tachycardia, hyperthermia, delirium, seizures, and death. There is no established safe dose for crude plant preparations, and the alkaloid content varies unpredictably between plant chemotypes, growth stages, and preparation methods. Multiple fatalities and severe poisonings have been documented globally from intentional and accidental ingestion of angel's trumpet plant material.

What does the scientific research say about Brugmansia suaveolens?

Preclinical research has identified 120 compounds in B. suaveolens and demonstrated measurable anti-inflammatory activity via NF-kB inhibition, p38α MAP kinase suppression (IC50 54.86 ± 2.82 µg/mL), and elastase inhibition (51.35 ± 0.69 µg/mL) in ethanol extract studies. Spasmolytic effects were confirmed in rabbit smooth muscle at 71.5 µg/mL. However, no controlled human clinical trials have evaluated the whole plant or traditional Roehrero preparation, meaning all potential therapeutic applications remain at the preclinical evidence stage.

What drugs does Brugmansia suaveolens interact with?

Brugmansia suaveolens interacts dangerously with any medication that has anticholinergic properties, including antihistamines (diphenhydramine), tricyclic antidepressants (amitriptyline), and antipsychotics (clozapine), producing additive receptor blockade and dramatically increasing toxicity risk. It also interacts with CNS depressants such as benzodiazepines and opioids, and pharmacologically opposes cholinesterase inhibitors like donepezil used in Alzheimer's treatment. These interactions make concurrent use with any prescription medication highly dangerous without medical supervision.

What are the differences between Brugmansia suaveolens and other Brugmansia species used traditionally?

Brugmansia suaveolens (angel's trumpet) contains primarily scopolamine and atropine, similar to other Brugmansia species, but differs in alkaloid ratios and concentration levels depending on plant part and growing conditions. B. suaveolens is traditionally used by Shipibo healers specifically for its spasmolytic and anti-inflammatory properties in ethnobotanical contexts. Other species like B. arborea and B. aurea may have different alkaloid profiles affecting their pharmacological potency and traditional applications.

How do the anticholinergic effects of Brugmansia suaveolens relate to its traditional medicinal uses?

The scopolamine and atropine in Brugmansia suaveolens block muscarinic receptors in smooth muscle, producing antispasmodic effects that may explain its traditional use for visceral cramping and respiratory conditions like bronchospasm. Research demonstrates these anticholinergic compounds are active at concentrations as low as 71.5 µg/mL in ethanol extracts, supporting the herb's ethnobotanical reputation for reducing muscle spasms. However, the margin between therapeutic and toxic anticholinergic doses remains extremely narrow, limiting safe clinical application.

What inflammatory pathways does Brugmansia suaveolens affect at the molecular level?

Ethanol extracts of Brugmansia suaveolens inhibit NF-κB signaling at 100 µg/mL concentration, a key transcription factor controlling pro-inflammatory cytokine production. This NF-κB inhibition suggests potential anti-inflammatory mechanisms distinct from its anticholinergic effects, indicating the plant contains multiple bioactive compounds with complementary pharmacological actions. The dual mechanism—spasmolytic and anti-inflammatory—may explain its traditional use for inflammatory conditions involving both muscular and immune components.

Roehrero

Brugmansia suaveolens contains tropane alkaloids—primarily scopolamine (hyoscine), atropine, and hyoscyamine—that act as competitive antagonists at muscarinic acetylcholine receptors, producing potent anticholinergic, deliriant, and spasmolytic effects across the central and peripheral nervous systems. In Shipibo ethnomedicine, scopolamine-dominant preparations are used as visionary plant medicines for ceremonial diagnosis and healing, with preclinical data showing NF-kB inhibition and elastase inhibition at 51.35 ± 0.69 µg/mL, though no controlled human clinical trials have established a safe therapeutic dose.

Category: Amazonian Evidence: 1/10 Tier: Preliminary

Origin & History

Brugmansia suaveolens, commonly called angel's trumpet, is native to the tropical regions of South America, particularly the Andean foothills and upper Amazonian basin spanning modern-day Peru, Ecuador, Colombia, and Brazil. It thrives in humid, warm montane environments between 500 and 3,000 meters elevation, often growing along riverbanks and forest margins with rich, well-drained soils. The plant has been cultivated for centuries by Amazonian peoples including the Shipibo-Conibo, who selectively propagate specific chemotypes for ritual and medicinal purposes.

Historical & Cultural Context

Among the Shipibo-Conibo people of the Peruvian Amazon, Brugmansia suaveolens is known by the name Roehrero and occupies a prominent place in the corpus of plant teachers (plant medicines used for visionary diagnosis and healing), employed by trained ayahuasceros and curanderos in structured ceremonial contexts to facilitate contact with healing spirits and diagnose illness. Pre-Columbian archaeological evidence from Andean cultures documents the use of Brugmansia species in burial offerings and shamanistic ritual, with ceramic representations suggesting use extending back at least 2,500 years across cultures including the Nazca and Chimú. Early Spanish colonial chroniclers, including José de Acosta in the late 16th century, documented Datura and Brugmansia preparations being used to induce states in which oracles were consulted and the dead were said to communicate—uses consistent with the anticholinergic delirium produced by tropane alkaloids. The plant is also historically documented in Andean folk medicine as a topical treatment for pain and inflammation, with flowers used in bath preparations and leaves applied as poultices, practices that persist in rural communities across Ecuador, Peru, and Colombia today.

Health Benefits

- **Anticholinergic and Spasmolytic Activity**: Scopolamine and atropine block muscarinic M1–M3 receptors in smooth muscle, producing antispasmodic effects demonstrated in rabbit smooth muscle preparations at 71.5 µg/mL of ethanol extract, suggesting potential in conditions involving visceral cramping or bronchospasm.
- **Anti-inflammatory Modulation**: Ethanol extracts at 100 µg/mL inhibit NF-kB binding to DNA and suppress p38α mitogen-activated protein kinase activity (IC50 54.86 ± 2.82 µg/mL), pathways central to the inflammatory cascade relevant to rheumatism and allergic conditions noted in traditional use.
- **Elastase Inhibition**: The same ethanol extract fraction demonstrated elastase inhibitory activity at 51.35 ± 0.69 µg/mL, indicating potential relevance to tissue-degradation-driven inflammatory diseases and connective tissue protection, though no human data exist.
- **Antioxidant Activity via Flavonoids**: Quercetin and kaempferol, identified among the plant's 120 compounds, act as free-radical scavengers and inhibitors of pro-oxidant enzymes, contributing to the plant's reported antioxidant properties in in vitro assays.
- **Visionary and Neurological Effects (Ethnopharmacological)**: Scopolamine crosses the blood-brain barrier and antagonizes central muscarinic receptors, producing the profound alteration in consciousness and vivid hypnagogic states central to Shipibo ceremonial use under the name Roehrero, with effects exploited clinically in motion sickness and anesthesia premedication at tightly controlled pharmaceutical doses.
- **Antimicrobial Potential**: Alkaloid and terpenoid fractions of B. suaveolens have demonstrated antimicrobial activity in preliminary in vitro screens, consistent with the plant's traditional use as a topical agent against infections, though mechanism and spectrum remain poorly characterized in peer-reviewed literature.
- **Analgesic Properties**: Traditional use as a topical analgesic for rheumatic pain is partially supported by the plant's anti-inflammatory alkaloid and flavonoid content, with central scopolamine-mediated analgesia also implicated, though no dose-response analgesic data from controlled studies are available.

How It Works

The primary mechanism of Brugmansia suaveolens is competitive, reversible antagonism at muscarinic acetylcholine receptors (M1–M5 subtypes) by its dominant tropane alkaloids—scopolamine, atropine, and hyoscyamine—blocking acetylcholine-mediated signal transduction in both the central nervous system and peripheral autonomic effector organs. Scopolamine exhibits preferential affinity for M1 receptors in the hippocampus and cortex, disrupting cholinergic neurotransmission and producing sedation, amnesia, and hallucinogenic states at elevated doses, while peripherally it reduces secretions, increases heart rate, and relaxes smooth muscle. The flavonoids quercetin and kaempferol contribute secondary anti-inflammatory effects by inhibiting IκB kinase and downstream NF-kB nuclear translocation, while also scavenging reactive oxygen species and inhibiting lipoxygenase and cyclooxygenase pathways. Suppression of p38α MAP kinase at IC50 54.86 ± 2.82 µg/mL further attenuates cytokine-driven inflammatory signaling, particularly TNF-α and IL-1β production, providing a molecular basis for the plant's ethnobotanical use in inflammatory and rheumatic conditions.

Scientific Research

The scientific evidence base for Brugmansia suaveolens as a whole plant or traditional preparation is limited almost exclusively to in vitro and animal pharmacology studies, with no registered human clinical trials specifically evaluating Roehrero or equivalent traditional preparations. Phytochemical analyses have characterized at least 120 compounds across various plant tissues, and mechanistic studies have quantified NF-kB inhibition, p38α suppression (IC50 54.86 ± 2.82 µg/mL), elastase inhibition (51.35 ± 0.69 µg/mL), and spasmolytic activity (71.5 µg/mL in rabbit smooth muscle), providing a credible mechanistic framework but no efficacy or safety data translatable to human dosing. The isolated constituent scopolamine has a robust independent clinical literature supporting its pharmaceutical use in motion sickness, postoperative nausea, and anesthesia (where transdermal patches delivering 1 mg over 72 hours are standard), but this cannot be extrapolated to crude plant preparations with variable alkaloid content. The overall evidence for the whole plant preparation as used in Shipibo tradition remains at the level of ethnopharmacological documentation and preclinical biochemistry, and the toxicological risk profile significantly constrains any clinical research pathway.

Clinical Summary

No controlled clinical trials have been conducted evaluating Brugmansia suaveolens or its traditional Shipibo preparation (Roehrero) as a whole-plant intervention in human subjects, making formal clinical summarization impossible. The pharmaceutical literature on purified scopolamine—the plant's dominant visionary alkaloid—documents efficacy for chemotherapy-induced nausea (NNT ~3–4 in systematic reviews) and motion sickness at transdermal doses of 1 mg/72 hours, establishing a pharmacological proof of concept for the plant's most bioactive constituent. Anti-inflammatory and antispasmodic outcomes measured in preclinical settings show measurable biological activity at concentrations achievable in vitro, but translation to in vivo human effect sizes has not been studied. Confidence in any therapeutic claim for the traditional whole-plant preparation is very low, and the narrow margin between psychoactive and toxic doses of tropane alkaloids makes controlled human trials ethically and logistically complex.

Nutritional Profile

Brugmansia suaveolens is not consumed as a nutritional food source and provides no meaningful macronutrient contribution in any traditional or clinical context. Its phytochemical profile, characterized across 120 identified compounds, includes tropane alkaloids (scopolamine, atropine, hyoscyamine, littorine, pseudotropine, tropine) as the pharmacologically dominant fraction, with scopolamine typically representing the highest concentration in flowers and seeds, though precise concentration data per gram of plant material are not uniformly reported in the literature. Flavonoid glycosides, primarily quercetin and kaempferol derivatives, contribute antioxidant capacity; terpenoids, steroids, and aromatic compounds have been identified but not individually quantified in available published analyses. Bioavailability of tropane alkaloids from oral preparations is variable and influenced by gastrointestinal pH, plant matrix, and individual hepatic metabolism via CYP3A4 and butyrylcholinesterase hydrolysis, meaning alkaloid exposure from crude preparations is highly unpredictable.

Preparation & Dosage

- **Traditional Shipibo Ceremonial Preparation (Roehrero)**: Bark, leaf, or flower decoctions prepared by initiated healers (curanderos) under strictly supervised ritual conditions; doses are individualized and not standardized—this preparation is NOT suitable for self-administration due to extreme toxicity risk.
- **Pharmaceutical Scopolamine (Extracted Constituent)**: Transdermal patch 1 mg delivered over 72 hours for motion sickness and postoperative nausea; oral scopolamine hydrobromide 0.3–0.6 mg for preoperative sedation under medical supervision.
- **Ethanol Extract (Research/Preclinical)**: Concentrations of 51–100 µg/mL used in in vitro studies; no safe or effective oral dose range for humans has been established from whole-plant extracts.
- **Topical Preparations (Traditional)**: Crushed leaves or flower poultices applied externally to joints in folk treatment of rheumatism; alkaloids are absorbed percutaneously, so systemic toxicity remains a risk even with topical use.
- **Standardization**: No commercially standardized supplement form exists; alkaloid content varies dramatically by plant part, geographic chemotype, growth stage, and preparation method, making dosage extrapolation between preparations unreliable.
- **Critical Warning**: There is NO established safe supplemental dose for whole-plant or crude extract preparations of B. suaveolens; the therapeutic-to-toxic ratio is extremely narrow, and self-administration has resulted in severe anticholinergic toxidrome and fatalities.

Synergy & Pairings

In Amazonian ceremonial practice, Roehrero is occasionally combined with ayahuasca preparations (Banisteriopsis caapi and Psychotria viridis) by experienced Shipibo healers, where beta-carboline MAO inhibitors from B. caapi may prolong and intensify the alkaloid effects of both DMT and scopolamine through monoamine oxidase inhibition—a combination that dramatically amplifies toxicity risk and is not recommended outside of tightly controlled traditional contexts. The flavonoid constituents quercetin and kaempferol may exhibit additive anti-inflammatory synergy with other NF-kB-targeting botanicals such as curcumin (Curcuma longa) and boswellic acids, though this has not been studied in the context of B. suaveolens specifically. Pharmacologically, the spasmolytic effects of scopolamine are enhanced by calcium channel antagonism, suggesting theoretical synergy with magnesium supplementation for smooth muscle relaxation, though again no data specific to this plant preparation exist.

Safety & Interactions

Brugmansia suaveolens poses serious and potentially life-threatening toxicity risks; atropine and scopolamine are responsible for anticholinergic toxidrome characterized by tachycardia, hyperthermia, mydriasis, urinary retention, delirium, hallucinations, seizures, and respiratory failure, with documented fatalities from ingestion of flowers, seeds, or unprepared leaf material. The plant interacts dangerously with antihistamines, tricyclic antidepressants, antipsychotics, and other anticholinergic agents through additive receptor blockade, and may potentiate CNS depressants including benzodiazepines and opioids; concurrent use with cholinesterase inhibitors (e.g., donepezil, physostigmine) produces pharmacological antagonism. Brugmansia preparations are absolutely contraindicated in pregnancy (potential teratogenicity and uterotonic activity have been reported in animal models), lactation, angle-closure glaucoma, benign prostatic hyperplasia, myasthenia gravis, and in individuals with cardiovascular arrhythmias. No maximum safe dose for whole-plant preparations has been established for humans, and all traditional uses involving ingestion carry an unacceptable safety risk outside of controlled ceremonial settings supervised by experienced practitioners; no form of self-medication or unsupervised supplementation is defensible given current evidence.